Becton, Dickinson and Company $BDX Shares Sold by Public Employees Retirement System of Ohio

Key Points

• The Public Employees Retirement System of Ohio reduced its stake in Becton, Dickinson and Company by 10.0%, resulting in 116,669 shares valued at approximately $20.1 million at the end of the second quarter.
• Becton, Dickinson and Company reported a 10.4% year-over-year revenue increase for the last quarter, with earnings per share of $3.68, surpassing analyst expectations.
• The company declared a quarterly dividend of $1.04 per share, equivalent to an annual yield of 2.3%, with a payout ratio of 74.82%.

Public Employees Retirement System of Ohio lowered its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 10.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 116,669 shares of the medical instruments supplier's stock after selling 12,904 shares during the period. Public Employees Retirement System of Ohio's holdings in Becton, Dickinson and Company were worth $20,096,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Northcape Wealth Management LLC raised its position in shares of Becton, Dickinson and Company by 0.5% in the first quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier's stock worth $2,248,000 after acquiring an additional 51 shares during the period. Alpha Omega Wealth Management LLC raised its position in shares of Becton, Dickinson and Company by 5.7% in the first quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock worth $225,000 after acquiring an additional 53 shares during the period. Brady Family Wealth LLC raised its position in shares of Becton, Dickinson and Company by 1.2% in the first quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier's stock worth $989,000 after acquiring an additional 53 shares during the period. Diversified Trust Co raised its position in shares of Becton, Dickinson and Company by 4.7% in the first quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier's stock worth $272,000 after acquiring an additional 53 shares during the period. Finally, Horizon Bancorp Inc. IN raised its position in shares of Becton, Dickinson and Company by 10.9% during the 1st quarter. Horizon Bancorp Inc. IN now owns 569 shares of the medical instruments supplier's stock worth $130,000 after purchasing an additional 56 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares of the company's stock, valued at $881,077.23. This represents a 19.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Claire Fraser sold 917 shares of the stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company's stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 2,965 shares of company stock valued at $551,536. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Stock Down 2.8%

BDX stock opened at $180.86 on Friday. The company has a market cap of $51.84 billion, a price-to-earnings ratio of 32.53, a PEG ratio of 1.50 and a beta of 0.27. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The firm has a 50-day moving average of $188.15 and a two-hundred day moving average of $189.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. The company had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Becton, Dickinson and Company's quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be paid a $1.04 dividend. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.3%. Becton, Dickinson and Company's dividend payout ratio is 74.82%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on BDX. Morgan Stanley upped their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Royal Bank Of Canada began coverage on shares of Becton, Dickinson and Company in a research report on Thursday. They set a "sector perform" rating and a $211.00 price target for the company. Piper Sandler restated a "neutral" rating and set a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Barclays reduced their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research report on Tuesday, June 3rd. Finally, Argus upped their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Four investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $213.09.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.